No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights
Home Compliance

iConsiderations for Apple as a Medical Device Manufacturer

by Mohan Ponnudurai
August 4, 2014
in Compliance
iConsiderations for Apple as a Medical Device Manufacturer

With the introduction of the MacBook, iPod, iPad and various iPhone iterations, Apple has proudly touted that its tech innovations have “changed everything” and “changed everything again.” Apple is poised to create yet another new segment in its path of innovation, as the company is currently in talks with the FDA to classify its latest technology, the iWatch, as a Class I or even Class II medical device. As such, it’s safe to say the tech giant is changing things once again, and has an opportunity to set an example for other manufacturers along the way.

Due to the fact that iWatch has the ability to capture, store and transmit many vital signs based on thresholds set by a health care professional, Apple claims that its regulated, wearable iWatches could be used to monitor patients and eventually integrate into patient health records. Getting clearance from the FDA means Apple will have broader appeal of who they can target for sales, but also means that Apple, as a medical device manufacturer, will have many new regulations to comply with and considerations to make.

While the technology may be user-friendly, low-cost and allow health care providers to offer more personalized care and advice to patients, what is the risk if the iWatch malfunctions? For example, if the iWatch reports healthy blood pressure levels but the wearer is actually in danger of – and goes into – cardiac arrest, Apple could find itself in the middle of a pretty serious product liability lawsuit. False positives or the patients/users making wrong decisions based on an erroneous display of measured elements can also be quite adverse, and even fatal.

DNA analysis company 23andMe knows this all too well, as the FDA recently forced the company to end the sale of its personal genome services (PGS). According to the FDA’s cease and desist letter1, “Some of the uses for which PGS is intended are particularly concerning…because of the potential health consequences that could result from false positive or false negative assessments… For instance, if the BRCA2-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery, chemoprevention, intensive screening or other morbidity-inducing actions, while a false negative could result in a failure to recognize an actual risk that may exist.” Apple, presumably, will want to avoid receiving a similar cease and desist letter at all costs. This can be done through the use of sophisticated software, extensive testing and managing ongoing activities with quality management software (QMS) to help ensure compliance with necessary safety regulations, in addition to streamlining and tracking product audits to find and remedy issues before the iWatch hits store shelves.

Not only does Apple claim the iWatch’s ability to make health assessments and recommendations, its recent hire of hardware developer Nancy Dougherty has spurred rumors that the device could come equipped with sophisticated sensors that are capable of tracking kidney and liver function, measuring electrolytes, and determining the amount of sugar in the blood in real time. According to Zeev Zalevsky, of Israel’s Bar-Ilan University, who studies blood sugar–monitoring devices, “Glucose is the holy grail of diagnostics.3”  What’s more – since diabetics are most at risk for plummeting blood glucose levels at night while they are asleep, wearables like the iWatch could be an indispensable tool to alert users of such instances. That said, an iWatch with these monitoring features would not be a toy or a fashion statement – it could easily be the difference between life and death for someone suffering from diabetes or another life-threatening disease.

Before the ubiquitous tech leader officially becomes a manufacturer of medical devices, it’s important for the company to think through the extensive regulatory and compliance demands ahead and have the processes and systems in place to become and remain compliant with industry regulations while ensuring quality is upheld throughout the iWatch’s entire life cycle, and be capable of training employees for such challenges. While Apple may be no stranger to customer complaints, as the company moves into the more heavily regulated world of medical devices, complaint management will be more crucial than ever. Don’t like the color of your iPhone? Oh well, buy a designer cover. Does your iWatch shock you when you sweat? That’s an issue that could prove harmful, and Apple will need to remedy it quickly. Complaint management software will be vital in identifying, logging, responding to and analyzing customer complaints and implementing QMS to assign responsibility and accountability for tasks is paramount.

Additionally, a QMS could help manage employee trainings to ensure compliance with government and industry regulations, in addition to maintaining a standard of excellence in controlling the training initiative. Centralized, comprehensive training records provide proof of compliance and an accurate reflection of training needs, while integration with quality-driven actions such as corrective action and preventive action (CAPA) plans and change control ensures that any additional training required due to events are enforced and carried out.

Without a doubt, Apple has shaken up the tech market in recent years, blazing the trail for new companies to follow suit. Apple is known for its attention to detail, product quality and reliability, however, not in the medical device industry where there is constant scrutiny by governmental regulatory bodies. In its pursuit for Class I or Class II medical device approvals from the FDA, it’s vital that Apple set an example for others by ensuring absolute quality, compliance and safety; otherwise, it and other medical device manufacturers could face the possibility of lawsuits and become iBankrupt.

1 http://m.bizjournals.com/sanjose/news/2013/11/25/fda-orders-24andme-to-halt-sales.html?page=all&r=full

2 The BRCA gene test is a blood test that uses DNA analysis to identify harmful changes (mutations) in either one of the two breast cancer susceptibility genes — BRCA1 and BRCA2 [http://www.mayoclinic.org/tests-procedures/brca-gene-test/basics/definition/prc-20020361]

3 http://www.mensjournal.com/health-fitness/exercise/apples-health-tracking-new-iwatch-what-we-know-20140625


Previous Post

FCPA Mid-Year Assessments

Next Post

Health Care Litigants Continue to Win Access to Risk Management Docs, LeClairRyan Attorneys Warn

Mohan Ponnudurai

Mohan Ponnudurai

Mohan Ponnudurai headshot 7-9-14Mohan Ponnudurai is an industry solution director at Sparta Systems Inc.,a global leader in enterprise quality management software (EQMS) solutions. With over 20 years’ experience,Mohan helps both the company and its clients in the high tech manufacturing (including medical device), oil and gas (energy and services) and electronics sectors understand industry trends, needs and requirements. Mohan earned his Bachelor’s Degree in Engineering from McGill University in Montreal, Canada, and MBA from the University of Tampa, Florida. In 2013, he was awarded the Supply & Demand Chain Executive “Pros to Know” Award for his exceptional leadership in Sparta Systems’ alignment with industry trends while helping clients understand changes in regulatory and business environments. Mohan is also an active participant at industry conference speaking engagements, white paper/article/blog authorship, analyst roadshows and product/solution thought leadership. Connect with Mohan: Mohan Ponnudurai
Sparta Systems, Inc.
2000 Waterview Drive, Suite 300
Hamilton, NJ
08691 mohan.ponnudurai@spartasystems.com

Related Posts

launch visual lease esg steward

Visual Lease Launches ESG Tool for Asset Portfolios

by Corporate Compliance Insights
March 31, 2023

Lease software provider Visual Lease announced it has launched a new product, VL ESG Steward,  designed to help organizations track...

PW FCPA Enforcement and Anticorruption 2022 Review_f

FCPA Enforcement & Anti-Corruption Developments

by Corporate Compliance Insights
March 30, 2023

The year that was in FCPA & anti-corruption efforts 2022: A Year in Review FCPA Enforcement & Anti-Corruption Developments What’s...

JTC ESG and Impact Investing_f

The Evolution of ESG & Impact Investing: Are You Ready?

by Corporate Compliance Insights
March 30, 2023

Making money *and* doing the right thing Survey Report The Evolution of ESG & Impact Investing: Are You Ready? What’s...

Regology 2023 State of Regulatory Compliance_f

2023 State of Regulatory Compliance

by Corporate Compliance Insights
March 30, 2023

Understanding the impact of regulatory challenges Survey Report 2023 State of Regulatory Compliance What’s in this report from Regology:As the...

Next Post
Health Care Litigants Continue to Win Access to Risk Management Docs, LeClairRyan Attorneys Warn

Health Care Litigants Continue to Win Access to Risk Management Docs, LeClairRyan Attorneys Warn

Compliance Job Interview Q&A

Jump to a Topic

AML Anti-Bribery Anti-Corruption Artificial Intelligence (AI) Automation Banking Board of Directors Board Risk Oversight Business Continuity Planning California Consumer Privacy Act (CCPA) Code of Conduct Communications Management Corporate Culture COVID-19 Cryptocurrency Culture of Ethics Cybercrime Cyber Risk Data Analytics Data Breach Data Governance DOJ Download Due Diligence Enterprise Risk Management (ERM) ESG FCPA Enforcement Actions Financial Crime Financial Crimes Enforcement Network (FinCEN) GDPR HIPAA Know Your Customer (KYC) Machine Learning Monitoring RegTech Reputation Risk Risk Assessment SEC Social Media Risk Supply Chain Technology Third Party Risk Management Tone at the Top Training Whistleblowing
No Result
View All Result

Privacy Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2022 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe

© 2022 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT